Doxazosin treatment attenuates carbon tetrachloride-induced liver fibrosis in hamsters through a decrease in transforming growth factor β secretion

Gut and Liver

Volumn 10, Issue 1, 2016, Pages 101-108

  Muñoz Ortega, Martin Humberto ^a   Llamas Ramírez, Raúl Wiliberto ^a   Romero Delgadillo, Norma Isabel ^a   Elías Flores, Tania Guadalupe ^a   De Jesus Tavares Rodríguez, Edgar ^a   Del Rosario Campos Esparza, María ^a   Cervantes García, Daniel ^a   Muñoz Fernández, Luis ^b   Gerardo Rodríguez, Martin ^a   Ventura Juárez, Javier ^a  

^a UNIVERSIDAD AUTÓNOMA DE AGUASCALIENTES   (Mexico)

^b Department of Pathology   (Mexico)

Author keywords

Adrenergic pathway; Adrenergic receptor antagonist; Cirrhosis; Collagen; Transforming growth factor beta

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; BIOCHEMICAL MARKER; CARVEDILOL; COLLAGEN TYPE 1; DOXAZOSIN; PLACEBO; TRANSFORMING GROWTH FACTOR BETA; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; CARBAZOLE DERIVATIVE; CARBON TETRACHLORIDE; PROPANOLAMINE DERIVATIVE; SERUM ALBUMIN;

ALPHA ADRENERGIC RECEPTOR BLOCKING; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BETA ADRENERGIC RECEPTOR BLOCKING; CARBON TETRACHLORIDE-INDUCED LIVER FIBROSIS; CONTROLLED STUDY; DRUG MECHANISM; HAMSTER MODEL; IMMUNOHISTOCHEMISTRY; LIVER BIOPSY; LIVER FUNCTION; LIVER FUNCTION TEST; LIVER PROTECTION; MALE; NONHUMAN; PROTEIN SECRETION; ANIMAL; BLOOD; CHEMICALLY INDUCED; DRUG EFFECTS; HAMSTER; LIVER; LIVER CIRRHOSIS; METABOLISM; PATHOLOGY;

ADRENERGIC ALPHA-1 RECEPTOR ANTAGONISTS; ALANINE TRANSAMINASE; ANIMALS; ASPARTATE AMINOTRANSFERASES; BILIRUBIN; CARBAZOLES; CARBON TETRACHLORIDE; COLLAGEN TYPE I; CRICETINAE; DOXAZOSIN; LIVER; LIVER CIRRHOSIS; LIVER FUNCTION TESTS; PROPANOLAMINES; SERUM ALBUMIN; TRANSFORMING GROWTH FACTOR BETA;

EID: 84957309448     PISSN: 19762283     EISSN: None     Source Type: Journal    
DOI: 10.5009/gnl14459     Document Type: Article

References (27)

1. Ueha S, Shand FH, Matsushima K. Cellular and molecular mechanisms of chronic inflammation-associated organ fibrosis. Front Immunol 2012;3:71.
2. Firpi RJ, Clark V, Soldevila-Pico C, et al. The natural history of hepatitis C cirrhosis after liver transplantation. Liver Transpl 2009; 15:1063-1071.
3. Aghemo A, Colombo M. Cirrhosis regression in chronic hepatitis C: an old tale with a new ending. Gastroenterology 2009;136:1447-1449.
4. Wynn TA. Cellular and molecular mechanisms of fibrosis. J Pathol 2008;214:199-210.
5. Holt AP, Salmon M, Buckley CD, Adams DH. Immune interactions in hepatic fibrosis. Clin Liver Dis 2008;12:861-882.
6. Genescà J, Buti M. Cytokines and liver cirrhosis. Med Clin 2004; 122:457-458.
7. Hellerbrand C. Molecular targets for antifibrotic therapy in liver disease: using magic bullets for crossfire rather than a one-sided shotgun attack. Gut 2014;63:1039-1041.
8. Sancho-Bru P, Bataller R, Colmenero J, et al. Norepinephrine induces calcium spikes and proinflammatory actions in human hepatic stellate cells. Am J Physiol Gastrointest Liver Physiol 2006;291:G877-G884.
9. Oben JA, Roskams T, Yang S, et al. Hepatic fibrogenesis requires sympathetic neurotransmitters. Gut 2004;53:438-445.
10. Oben JA, Roskams T, Yang S, et al. Sympathetic nervous system inhibition increases hepatic progenitors and reduces liver injury. Hepatology 2003;38:664-673.
11. Dubuisson L, Desmouliere A, Decourt B, et al. Inhibition of rat liver fibrogenesis through noradrenergic antagonism. Hepatology 2002;35:325-331.
12. Tripathi D, Hayes PC. The role of carvedilol in the management of portal hypertension. Eur J Gastroenterol Hepatol 2010;22:905-911.
13. Dandona P, Ghanim H, Brooks DP. Antioxidant activity of carvedilol in cardiovascular disease. J Hypertens 2007;25:731-741.
14. Hamdy N, El-Demerdash E. New therapeutic aspect for carvedilol: antifibrotic effects of carvedilol in chronic carbon tetrachloride-induced liver damage. Toxicol Appl Pharmacol 2012;261:292-299.
15. Lepor H. The evolution of alpha-blockers for the treatment of benign prostatic hyperplasia. Rev Urol 2006;8 Suppl 4:S3-S9.
16. Gressner AM, Weiskirchen R. Modern pathogenetic concepts of liver fibrosis suggest stellate cells and TGF-beta as major players and therapeutic targets. J Cell Mol Med 2006;10:76-99.
17. Junqueira LC, Cossermelli W, Brentani R. Differential staining of collagens type I, II and III by Sirius Red and polarization microscopy. Arch Histol Jpn 1978;41:267-274.
18. Roskams T, Cassiman D, De Vos R, Libbrecht L. Neuroregulation of the neuroendocrine compartment of the liver. Anat Rec A Discov Mol Cell Evol Biol 2004;280:910-923.
19. Motoyama H, Komiya T, Thuy le TT, et al. Cytoglobin is expressed in hepatic stellate cells, but not in myofibroblasts, in normal and fibrotic human liver. Lab Invest 2014;94:192-207.
20. Komeda K, Takai S, Jin D, et al. Chymase inhibition attenuates tet-rachloride-induced liver fibrosis in hamsters. Hepatol Res 2010;40: 832-840.
21. Popper H. Pathologic aspects of cirrhosis: a review. Am J Pathol 1977;87:228-264.
22. Santra A, Chowdhury A, Ghosh A, Mazumder DN. Development of an animal model of hepatic fibrosis by excretory-secretory antigen of Ascaris suum. Indian J Gastroenterol 2000;19:119-121.
23. Gallego-Delgado J, Lazaro A, Gomez-Garre D, et al. Long-term organ protection by doxazosin and/or quinapril as antihypertensive therapy. J Nephrol 2006;19:588-598.
24. Perlini S, Palladini G, Ferrero I, et al. Sympathectomy or doxazo-sin, but not propranolol, blunt myocardial interstitial fibrosis in pressure-overload hypertrophy. Hypertension 2005;46:1213-1218.
25. Pawluczyk IZ, Patel SR, Harris KP. The role of the alpha-1 adre-noceptor in modulating human mesangial cell matrix production. Nephrol Dial Transplant 2006;21:2417-2424.
26. Shi MN, Huang YH, Zheng WD, Zhang LJ, Chen ZX, Wang XZ. Relationship between transforming growth factor beta1 and anti-fibrotic effect of interleukin-10. World J Gastroenterol 2006;12:2357-2362.
27. Aldaba-Muruato LR, Moreno MG, Shibayama M, Tsutsumi V, Muriel P. Allopurinol reverses liver damage induced by chronic carbon tetrachloride treatment by decreasing oxidative stress, TGF-beta production and NF-kappaB nuclear translocation. Pharmacology 2013; 92:138-149.